知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

30 条记录 (耗时 0.034 秒)

    [6,5]—bicyclic GPR119 G protein-coupled receptor agonists
    1.
    发明授权
    [6,5]—bicyclic GPR119 G protein-coupled receptor agonists 有权
    [6,5] - 双环GPR119 G蛋白偶联受体激动剂

    公开(公告)号：US08476283B2

    公开(公告)日：2013-07-02

    申请号：US13307698

    申请日：2011-11-30

    申请人： John M. Fevig ,  Dean A. Wacker

    发明人： John M. Fevig ,  Dean A. Wacker

    IPC分类号： A01N43/90 ,  A61K31/519 ,  C07D487/00

    CPC分类号： C07D471/04 ,  C07D473/34 ,  C07D487/04

    摘要： Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein n2, n3, n4, A, B, D, E, G, J, Y, R1 and R2 are defined herein.

    摘要翻译： 提供了新的化合物，它们是GPR119G蛋白偶联受体调节剂。 GPR119 G蛋白偶联受体调节剂可用于治疗，预防或减缓需要GPR119 G蛋白偶联受体调节剂治疗的疾病进展。 这些新化合物具有以下结构：或其立体异构体或前药或其药学上可接受的盐，其中n2，n3，n4，A，B，D，E，G，J，Y，R1和R2如本文所定义。

    7,8-DIHYDRO-1,6-NAPHTHYRIDIN-5(6H)-ONES AND RELATED BICYCLIC COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS
    3.
    发明申请
    7,8-DIHYDRO-1,6-NAPHTHYRIDIN-5(6H)-ONES AND RELATED BICYCLIC COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS 有权
    7,8-二氢-1,6-萘二酮-5（6H） - 酮和相关双酚化合物作为DIPEPTIDYL PEPTIDASE IV的抑制剂和方法

    公开(公告)号：US20090149492A1

    公开(公告)日：2009-06-11

    申请号：US11941181

    申请日：2007-11-16

    申请人： John M. Fevig ,  Jianxin Feng

    发明人： John M. Fevig ,  Jianxin Feng

    IPC分类号： A61K31/4375 ,  C07D471/04 ,  A61P3/10

    CPC分类号： C07D471/04

    摘要： The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an DPP4 modulated disease or disorder such as, for example, diabetes, by administration of a therapeutically effective dose of a compound according to Formula I. wherein X, Z, A, R2, Y, R1, n, and b are as defined herein.

    摘要翻译： 本申请提供化合物，包括根据式I的所有立体异构体，溶剂合物，前药和药学上可接受的形式。另外，本申请提供含有至少一种根据式I的化合物和任选的至少一种另外的治疗剂的药物组合物。 最后，本申请提供了通过施用治疗有效剂量的根据式I的化合物治疗患有DPP4调节的疾病或病症例如糖尿病的患者的方法。其中X，Z，A，R 2 ，Y，R 1，n和b如本文所定义。

    Substituted pyridoindoles as serotonin agonists and antagonists
    4.
    发明授权
    Substituted pyridoindoles as serotonin agonists and antagonists 有权
    取代的吡啶并吲哚作为血清素激动剂和拮抗剂

    公开(公告)号：US06849619B2

    公开(公告)日：2005-02-01

    申请号：US10784064

    申请日：2004-02-20

    申请人： Albert J. Robichaud ,  John M. Fevig ,  Ian S. Mitchell ,  Taekyu Lee ,  Wenting Chen ,  Joseph Cacciola

    发明人： Albert J. Robichaud ,  John M. Fevig ,  Ian S. Mitchell ,  Taekyu Lee ,  Wenting Chen ,  Joseph Cacciola

    IPC分类号： C07D471/16 ,  C07D498/16 ,  C07D513/16 ,  A61K31/33 ,  A61K31/55 ,  C07D223/14 ,  C07D245/00 ,  C07D267/02

    CPC分类号： C07D471/16 ,  C07D498/16 ,  C07D513/16

    摘要： The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6, R7, R8, R9, X, b, k, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

    摘要翻译： 本发明涉及由结构式（I）表示的某些新化合物或其药学上可接受的盐形式，其中R 1，R 5，R 6，R 7，R 8，R <9>，X，b，k和n，这里描述虚线。 本发明还涉及包含这些新化合物作为活性成分的药物制剂，以及新型化合物及其制剂在治疗某些疾病中的用途。 本发明的化合物是血清素激动剂和拮抗剂，可用于控制或预防中枢神经系统疾病，包括肥胖症，焦虑症，抑郁症，精神病，精神分裂症，睡眠障碍，性障碍，偏头痛，与头痛相关的病症，社交恐怖症 ，以及胃肠道疾病如胃肠道运动功能障碍。